

Marc L Berger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9251039/publications.pdf>

Version: 2024-02-01

58
papers

4,475
citations

186265
28
h-index

138484
58
g-index

59
all docs

59
docs citations

59
times ranked

4940
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification and Fracture Outcomes of Undiagnosed Low Bone Mineral Density in Postmenopausal Women. JAMA - Journal of the American Medical Association, 2001, 286, 2815.	7.4	1,006
2	Osteoporosis and Fracture Risk in Women of Different Ethnic Groups. Journal of Bone and Mineral Research, 2004, 20, 185-194.	2.8	459
3	Good Research Practices for Comparative Effectiveness Research: Defining, Reporting and Interpreting Nonrandomized Studies of Treatment Effects Using Secondary Data Sources: The ISPOR Good Research Practices for Retrospective Database Analysis Task Force Reportâ€”Part I. Value in Health, 2009, 12, 1044-1052.	0.3	305
4	Prediction of Fracture Risk in Postmenopausal White Women With Peripheral Bone Densitometry: Evidence From the National Osteoporosis Risk Assessment. Journal of Bone and Mineral Research, 2002, 17, 2222-2230.	2.8	284
5	Good Practices for Real-World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPORâ€”SPE Special Task Force on Real-World Evidence in Health Care Decision Making. Value in Health, 2017, 20, 1003-1008.	0.3	243
6	A metaanalysis of severe upper gastrointestinal complications of nonsteroidal antiinflammatory drugs. Journal of Rheumatology, 2002, 29, 804-12.	2.0	166
7	Prospective Observational Studies to Assess Comparative Effectiveness: The ISPOR Good Research Practices Task Force Report. Value in Health, 2012, 15, 217-230.	0.3	151
8	Measuring the effects of work loss on productivity with team production. Health Economics (United Kingdom), 2008, 29, 177-197.	1.7	147
9	Valuing reductions in on-the-job illness: â€”presenteeismâ€” from managerial and economic perspectives. Health Economics (United Kingdom), 2008, 29, 469-485.	1.7	136
10	A general model of the impact of absenteeism on employers and employees. Health Economics (United Kingdom), 2008, 29, 127-147.	1.7	127
11	CCl4-induced toxicity in isolated hepatocytes: The importance of direct solvent injury. Hepatology, 1986, 6, 36-45.	7.3	114
12	GRACE principles: recognizing high-quality observational studies of comparative effectiveness. American Journal of Managed Care, 2010, 16, 467-71.	1.1	103
13	A Questionnaire to Assess the Relevance and Credibility of Observational Studies to Inform Health Care Decision Making: An ISPOR-AMCP-NPC Good Practice Task Force Report. Value in Health, 2014, 17, 143-156.	0.3	96
14	Opportunities and challenges in leveraging electronic health record data in oncology. Future Oncology, 2016, 12, 1261-1274.	2.4	82
15	Identifying the Need for Good Practices in Health Technology Assessment: Summary of the ISPOR HTA Council Working Group Report on Good Practices in HTA. Value in Health, 2019, 22, 13-20.	0.3	76
16	Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0. Value in Health, 2017, 20, 1009-1022.	0.3	70
17	Intervention in free radical mediated hepatotoxicity and lipid peroxidation by indole-3-carbinol. Biochemical Pharmacology, 1988, 37, 333-338.	4.4	68
18	Recency and duration of postmenopausal hormone therapy: effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment (NORA) study. Menopause, 2003, 10, 412-419.	2.0	67

#	ARTICLE	IF	CITATIONS
19	Do NSAIDs cause dyspepsia? a meta-analysis evaluating alternative dyspepsia definitions. American Journal of Gastroenterology, 2002, 97, 1951-1958.	0.4	57
20	Comparative Effectiveness: Asking The Right Questions, Choosing The Right Method. Health Affairs, 2005, 24, 128-132.	5.2	49
21	Impact of 3-tier pharmacy benefit design and increased consumer cost-sharing on drug utilization. American Journal of Managed Care, 2005, 11, 621-8.	1.1	47
22	Optimizing the Leveraging of Real-World Data to Improve the Development and Use of Medicines. Value in Health, 2015, 18, 127-130.	0.3	45
23	Treatment of Migraine With Rizatriptan: When to Take the Medication. Headache, 2002, 42, 16-20.	3.9	43
24	Big data, advanced analytics and the future of comparative effectiveness research. Journal of Comparative Effectiveness Research, 2014, 3, 167-176.	1.4	39
25	Toxicity of methylating agents in isolated hepatocytes. Biochemical Pharmacology, 1988, 37, 3183-3188.	4.4	31
26	Anoxic hepatocyte injury: Role of reversible changes in elemental content and distribution. Hepatology, 1989, 9, 219-228.	7.3	30
27	Pharmacoeconomic analysis of caspofungin versus liposomal amphotericin B as empirical antifungal therapy for neutropenic fever. American Journal of Health-System Pharmacy, 2007, 64, 637-643.	1.0	30
28	How to Present the Business Case for Healthcare Quality to Employers. Applied Health Economics and Health Policy, 2005, 4, 209-218.	2.1	28
29	Caspofungin versus amphotericin B for candidemia: A pharmacoeconomic analysis. Clinical Therapeutics, 2005, 27, 960-969.	2.5	27
30	Getting Real Performance Out of Pay-for-Performance. Milbank Quarterly, 2008, 86, 435-457.	4.4	25
31	Carbon tetrachloride-induced morphologic alterations in isolated rat hepatocytes. Experimental and Molecular Pathology, 1987, 46, 245-257.	2.1	23
32	Scurvy as an Initial Manifestation of Whipple's Disease. Annals of Internal Medicine, 1984, 101, 58.	3.9	22
33	Big Data: transforming drug development and health policy decision making. Health Services and Outcomes Research Methodology, 2016, 16, 92-102.	1.8	20
34	Comparison of the effects on quality of life and of the efficacy and tolerability of lovastatin versus pravastatin. American Journal of Cardiology, 1996, 77, 475-479.	1.6	19
35	Utilization of Positive and Negative Controls to Examine Comorbid Associations in Observational Database Studies. Medical Care, 2017, 55, 244-251.	2.4	18
36	A randomized controlled open trial of population-based disease and case management in a Medicare Plus Choice health maintenance organization. Preventing Chronic Disease, 2004, 1, A05.	3.4	17

#	ARTICLE	IF	CITATIONS
37	Rapid halogenated hydrocarbon toxicity in isolated hepatocytes is mediated by direct solvent effects. <i>Toxicology</i> , 1987, 45, 319-330.	4.2	16
38	Evidence Synthesis and Evidence-Based Decision Making: Related But Distinct Processes. <i>Medical Decision Making</i> , 2005, 25, 487-489.	2.4	15
39	Efficient Patient Identification Strategies for Women with Osteoporosis. <i>Journal of Clinical Densitometry</i> , 1999, 2, 223-231.	1.2	14
40	The Once and Future Application of Cost-Effectiveness Analysis. <i>The Joint Commission Journal on Quality Improvement</i> , 1999, 25, 455-461.	1.5	13
41	Cost-Effectiveness Analysis. <i>Medical Care</i> , 2005, 43, II-49.	2.4	13
42	Comparative Effectiveness Research. <i>Pharmacoeconomics</i> , 2010, 28, 915-922.	3.3	13
43	The role of private industry in pragmatic comparative effectiveness trials. <i>Journal of Comparative Effectiveness Research</i> , 2012, 1, 147-156.	1.4	13
44	A Comparison of the Tolerability and Efficacy of Lovastatin 20 mg and Fluvastatin 20 mg in the Treatment of Primary Hypercholesterolemia. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 1996, 1, 101-106.	2.0	12
45	Effectiveness of antihyperlipidemic drug management in clinical practice. <i>Clinical Therapeutics</i> , 1999, 21, 1973-1987.	2.5	12
46	Quality-of-life questionnaire for patients taking antihypertensive medication. <i>Clinical Therapeutics</i> , 1999, 21, 1771-1787.	2.5	12
47	A Population-Based Approach to Asthma Disease Management. <i>Disease Management and Health Outcomes</i> , 2000, 7, 179-186.	0.4	12
48	Growth in use of lipid-lowering therapies: are we targeting the right patients?. <i>American Journal of Managed Care</i> , 2002, 8, 862-7.	1.1	10
49	Novel Oral Medication Delivery System for Famotidine. <i>Journal of Clinical Pharmacology</i> , 1995, 35, 362-367.	2.0	9
50	Toward Facilitated Self-Service in Health Care. <i>New England Journal of Medicine</i> , 2019, 380, 1891-1893.	27.0	9
51	The Decision to Conduct a Head-to-Head Comparative Trial: A Game-Theoretic Analysis. <i>Medical Decision Making</i> , 2007, 27, 364-379.	2.4	6
52	Raising the Bar of Efficacy for Drug Approval Requires an Understanding of Patient Diversity. <i>Journal of Clinical Oncology</i> , 2010, 28, e343-e344.	1.6	6
53	Do disease management programs for patients with coronary heart disease make a difference? Experiences of nine practices. <i>American Journal of Managed Care</i> , 2002, 8, 937-46.	1.1	5
54	Studies on calcium transport during carbon tetrachloride mediated hepatotoxicity in mice. <i>Biochemical Pharmacology</i> , 1988, 37, 4584-4586.	4.4	4

#	ARTICLE	IF	CITATIONS
55	The Value of Disease Management. Disease Management and Health Outcomes, 2000, 8, 181-184.	0.4	4
56	Can the pharmaceutical industry embrace comparative effectiveness research? A view from inside. Expert Review of Pharmacoeconomics and Outcomes Research, 2013, 13, 565-568.	1.4	3
57	Disease Management: An Intermediate Step Toward Integrated and Coordinated Patient Care. Disease Management: DM, 2001, 4, 173-178.	1.0	2
58	Bone Mineral Density Thresholds for Pharmacologic Intervention to Prevent Fractures. Obstetrical and Gynecological Survey, 2004, 59, 769-771.	0.4	2